Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GROINSS-V III: Sentinel Node-Positive Early Vulvar Cancer Treated With Adjuvant Chemoradiation
2016-003973-16Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and carboplatin in vulvar squamous cell carcinoma (VSCC), sponsored by University Medical Center Groningen. Primary endpoint: Groin recurrence rate at 2 years. Started Mar 2019; status: active.
02
Drugs
cisplatincarboplatin
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2016-003973-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003973-16.